DMC Recommends Biophytis Continue Sarconeos COVID-19 Study

• The Data Monitoring Committee (DMC) has recommended Biophytis SA (NASDAQ: BPTS) to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after reviewing of safety data.

• The COVA clinical program is assessing Sarconeos (BIO101) in patients aged 45 and older hospitalized with severe respiratory manifestations of COVID-19.

• The independent DMC meeting was dedicated to analyzing safety data from the first 155 randomized patients.

• The DMC will review the efficacy data of the 155 patients in Q3 2021 as part of the second Interim analysis to recommend futility and final sample size.

• The Company is progressing to complete the recruitment of the 310 patients and report top-line results in Q4 of 2021.

• Price Action: BPTS shares closed 1.27% higher at $8.54 on Friday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.